Estonia, our previous destination by the Baltic Sea, was a delightful and a full of potential place to visit.
This week, we are heading down to the relaxing and sunny south of France, more precisely to Toulouse, once the capital of the Visigothic Kingdom and current to the Midi-Pyrénées region, the largest region in metropolitan France.
It is also where Genticel, our Biotech of the Week, is located!
City: Toulouse (France)
Employees: 33 (as of 11/2015)
Financial Data: €96.26M Market Cap
CEO: Benedikt Timmerman
Genticel is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus (HPV), which causes around 70% of cases of cervical cancer.
With its two leading molecules, Genticel is the first company to have established a staged pipeline of HPV therapeutic vaccines for the large female population burdened with this unmet medical need.